SCHEDULE: Vanguard Portfolio Management Increases Stake in Ultragenyx

Vanguard Portfolio Management has reported a beneficial ownership of 6.95% in Ultragenyx Pharmaceutical Inc. as of June 30, 2026.

Summary

• Vanguard Portfolio Management, through its affiliates and managed accounts, now beneficially owns 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock.
• This represents 6.95% of the class of securities.
• The filing is an amendment to a previous Schedule 13G, indicating a change in ownership or reporting status.
• Vanguard Portfolio Management has sole dispositive power over all 6,853,427 shares.
• They also have sole voting power over 63,292 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive signal, indicating sustained institutional interest without immediate implications for company operations.

Positives

• Vanguard Portfolio Management's increased stake suggests confidence in Ultragenyx Pharmaceutical Inc.'s long-term prospects.
• The significant beneficial ownership by a major institutional investor can be seen as a positive signal to the market.

Future Outlook

This filing does not contain specific forward-looking statements or guidance from Ultragenyx Pharmaceutical Inc. It solely reports on Vanguard Portfolio Management's ownership stake.

Industry Context

StockSavvy.ai notes that significant shifts in beneficial ownership by large asset managers like Vanguard can signal evolving investor sentiment towards biotechnology and pharmaceutical companies, particularly those focused on rare diseases like Ultragenyx.

Stakeholder Impact

• Shareholders may view the increased stake by a major institutional investor as a sign of confidence, potentially supporting share price stability or growth.
• The filing does not directly impact employees, customers, suppliers, or creditors, as it pertains to share ownership.

Key Dates

Recommendation

The filing indicates a significant ownership stake by a major institutional investor, suggesting sustained interest. However, without specific operational or financial updates from Ultragenyx, a 'hold' recommendation is prudent, awaiting further company disclosures.

Keywords

Ultragenyx Pharmaceutical, Vanguard Portfolio Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Securities Ownership